Shanghai ZJ Bio-Tech Co (SHSE:688317) EBIT: ¥-46.1 Mil (TTM As of Mar. 2026)


SHSE:688317 Shanghai ZJ Bio-Tech Co Ltd SHSE:688317
68 GF Score
Price ¥15.68
GF Value ¥9.94
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Shanghai ZJ Bio-Tech Co EBIT?

Shanghai ZJ Bio-Tech Co SHSE:688317 -4.33% 68 EBIT is ¥-46.1 Mil as of Mar. 2026. GuruFocus rates SHSE:688317 with a GF Score™ of 68/100 and a GF Value™ of ¥9.94 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Shanghai ZJ Bio-Tech Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥-22.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-46.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shanghai ZJ Bio-Tech Co's annualized ROC % for the quarter that ended in Mar. 2026 was -11.31%. Shanghai ZJ Bio-Tech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -14.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shanghai ZJ Bio-Tech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -7.44%.


Shanghai ZJ Bio-Tech Co  (SHSE:688317) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shanghai ZJ Bio-Tech Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-91.104 * ( 1 - 0% )/( (799.386 + 810.956)/ 2 )
=-91.104/805.171
=-11.31 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3763.8 - 104.8 - ( 2900.624 - max(0, 126.583 - 2986.197+2900.624))
=799.386

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3706.727 - 97.32 - ( 2826.199 - max(0, 115.705 - 2914.156+2826.199))
=810.956

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shanghai ZJ Bio-Tech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-89.912/( ( (628.223 + max(-30.408, 0)) + (614.986 + max(-19.776, 0)) )/ 2 )
=-89.912/( ( 628.223 + 614.986 )/ 2 )
=-89.912/621.6045
=-14.46 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(31.243 + 45.573 + 7.6180000000004) - (104.8 + 0 + 10.042)
=-30.408

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(30.036 + 49.313 + 6.9469999999997) - (97.32 + 0 + 8.752)
=-19.776

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shanghai ZJ Bio-Tech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-46.11/619.889
=-7.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai ZJ Bio-Tech Co EBIT Related Terms


Shanghai ZJ Bio-Tech Co EBIT Historical Data

* Premium members only.

The historical data trend for Shanghai ZJ Bio-Tech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai ZJ Bio-Tech Co EBIT Chart

Shanghai ZJ Bio-Tech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 911.85 901.95 -156.28 -150.23 -38.63

Shanghai ZJ Bio-Tech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.00 8.38 -17.24 -14.77 -22.48

SHSE:688317 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Shanghai ZJ Bio-Tech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai ZJ Bio-Tech Co EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shanghai ZJ Bio-Tech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai ZJ Bio-Tech Co's EV-to-EBIT falls into.


SHSE:688317
68GF Score
Shanghai ZJ Bio-Tech Co Ltd SHSE:688317
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai ZJ Bio-Tech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-46.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥-46.1 Mil mean?
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a EBIT of ¥-46.1 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai ZJ Bio-Tech Co.
Is Shanghai ZJ Bio-Tech Co's EBIT too high?
Shanghai ZJ Bio-Tech Co's current EBIT is ¥-46.1 Mil. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's EBIT compare to ABT and SYK?
Shanghai ZJ Bio-Tech Co's EBIT of ¥-46.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shanghai ZJ Bio-Tech Co. Shanghai ZJ Bio-Tech Co's current EBIT is ¥-46.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.94, compared to a current price of ¥15.68 — trading 57.7% above its estimated fair value. The current EBIT is ¥-46.1 Mil. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current EBIT is ¥-46.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued. The current stock price of ¥15.68 is trading 57.7% above its estimated GF Value™ of ¥9.94. GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.

Key valuation signals for SHSE:688317:

  • EBIT: ¥-46.1 Mil
  • GF Value™: ¥9.94 vs. price of ¥15.68 (57.7% above fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shanghai ZJ Bio-Tech Co Business Description

Address No. 588 Xinjun Ring Road, Building 26, Pujiang Hi-Tech Park, Caohejing Development Zone, Shanghai, CHN
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
68GF Score

Get the complete analysis for SHSE:688317

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.68
Price
¥9.94
GF Value